Skip to main content

Spinal fluid test distinguished MS from similar diseases

By MS Buddy ·

Summarized from Cell, Apr 2026 · PubMed. AI-generated summary. Not medical advice.

Observational study · 5,000 people with MS and other neurological disorders

Research by Jakob Maximilian Bader, Matthias Mann and 17 colleagues at Max Planck Institute of Biochemistry, the Technical University of Munich and 2 other institutions in Germany and Denmark.

Can a spinal fluid test tell MS from similar inflammatory diseases?

Key Takeaway

A new spinal fluid test distinguished MS from related inflammatory diseases, including challenging cases.

Spinal cord cross-section surrounded by pale fluid and fine nerve fibers.
Credibility
Interest
Share:1 min read

What They Found

Researchers measured proteins in spinal fluid from people with a range of neurological disorders. They found changes linked to age, sex, and how well the barrier between blood and spinal fluid was working. In MS, a group of 22 proteins distinguished it from related inflammatory diseases. The group performed better than established markers in challenging cases and was confirmed in a separate group. Protein patterns also helped place people along a range from relapsing to progressive MS and were linked to clinical outcomes.

Who Should Care and Why

The study included people with MS and people with other neurological disorders. It focused on whether spinal fluid could help tell MS apart from similar inflammatory diseases. That question matters when a diagnosis is hard to make. Researchers also studied how protein patterns differed across relapsing and progressive MS. The findings concern a lab test, not a treatment.

Important Considerations

You should know this was a study of spinal fluid samples from 5,000 people, not a treatment trial. The abstract does not say how many people had MS or give the test's exact accuracy. It does not show whether using the test improves care for you.

AI-generated summary — for informational purposes only, not medical advice

Read the original abstract

Published in Cell by et al.. Reproduced from the PubMed record.

Cerebrospinal fluid (CSF) is central to neurological diagnostics, yet biomarkers are lacking for many clinical needs. To enable its large-scale proteomic characterization, we developed a high-throughput mass spectrometry workflow quantifying approximately 1,500 proteins per CSF sample across 5,000 individuals, covering a spectrum of neurological disorders. This revealed proteomic alterations associated with blood-CSF barrier impairment, age, and sex, enabling deconvolution of shared and disease-specific signatures. We then focused on multiple sclerosis (MS), using an improved analytical technology that quantified 2,100 proteins per sample. From these data, we derived a 22-protein panel that distinguished MS from related inflammatory diseases and outperformed established markers in challenging cases. A targeted mass spectrometry assay using isotope-labeled standards validated this panel in an independent cohort, offering a clinically compatible format. Additionally, we highlight proteins of therapeutic interest and demonstrate proteome-based staging of individuals along the relapsing-progressive MS spectrum, which correlates with clinical outcomes.

The app

Check out the MS Buddy app

It’s free, with no ads. Built by people living with MS.

Download on the App StoreGet it on Google Play

Related MS research

Two soft, overlapping layers sweep across muted dots, with a small cluster clearer through one layer.
Spinal fluid test flagged MS cases another test missed

11/20/2026

In a study of 140 people, a spinal fluid test better separated MS from other nervous system conditio

Read More
A crisp scan slice lines up with parallel strokes, while a fainter slice tilts across them.
Lining up MS brain scans gave stronger scan readings

11/20/2026

In people with MS, brain scan readings were stronger when images lined up with the scanner’s magneti

Read More
Overlapping blue-gray and lavender layers with small patches, aligned contours and a short, gently curving path.
AI scan tool improved MS checks and saved reading time

11/20/2026

A study of 59 people with relapsing-remitting MS found a computer tool helped doctors read brain sca

Read More
Cut-paper eye and ribbon-like nerve with a small overlapping terracotta shape on a warm off-white background.
MS linked to about 9% of eye nerve inflammation in Japan

11/19/2026

A Japanese hospital study linked MS to about 9% of first eye nerve inflammation cases. Other immune

Read More
Two matching brain lesion shapes, with a central vein faint on the left and more clearly visible on the right.
Adjusted MRI spots more veins inside MS brain lesions

11/18/2026

An adjusted MRI scan found more veins within MS brain lesions in 17 people with MS. It improved scan

Read More
Muted blue and clay ribbons curve across an off-white background, wrapped in soft layers of varying thickness.
Planned MS study will test scans to track worsening

11/16/2026

A planned study will use detailed brain scans and blood tests to explore why relapsing-remitting MS

Read More

Not all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.